52 Weeks Range: 0.08 - 1.47
Average Price Target: 0.39
Price Target Upside/Downside: -0.065

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.3000
-0.0380 (-11.24%)
At close: 3:59PM EST

International Equities Corporation Ltd (IEQ)
Share Price Activity
Last (Price) $0.035
Change 0.00 (0.00)
Bid / Ask $0.021 - ‐
Volume 0
Volume (4w avg) 0
Turnover $0
Open ‐
Day Range ‐ - ‐
VWAP ‐
Prev Close $0.035
Last Trade 6:58pm 25/01 (AEDT)

Historical Data
Year Closing Price Last Trade
2020 $0.035 30 June
2019 $0.035 28 June
2018 $0.04 29 June
2017 $0.066 28 June
2016 $0.066 28 June
2015 $0.06 30 June
2014 $0.06 30 June

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2867
-0.0200 (-6.52%)At close: January 15 3:59PM EST

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.3067
-0.0378 (-10.97%)
At close: 3:59PM EST

https://www.klsescreener.com/v2/news/view/735539/anatomy-of-stock-market-scams

Anatomy of stock market scams
TheStar Sat, Oct 03, 2020 09:40am

"Thirdly, one must look out for companies raising money through share placements, especially if the proceeds are to be used as working capital or to repay loans. The smaller the amount raised through a placement, the higher the scrutiny it warrants.

Also, if the bulk is used to repay loans, there is also a possibility of the company taking up more loans again. So, why risk taking up a stake in such companies?

Bintai raised money through Private Placement to partially pay it's debts of RM160 million.

Search: Generex

Candidate : No name announced

Mechanism : Ii-Key peptide COVID-19 vaccine

Sponsor : Generex Biotechnology

Trial Phase : Pre-clinical

Institution : Generex

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2265
-0.0135 (-5.62%)
At close: 3:55PM EST

Avg Volume (4 weeks): 95,434,827
4 Weeks Range: 0.56 - 1.26
52 Weeks Range: 0.04 - 1.47

Obviously investors paying for Bintai's Debts.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3117619

Proposed settlement of the outstanding debt owing by Optimal Property Management Sdn Bhd ("OPM"), a wholly-owned subsidiary of BKCB of RM23,397,091.37 to Handal Jayabina Sdn Bhd via the issuance and allotment of 31,800,000 new ordinary shares in BKCB, 28,500 new ordinary shares in OPM and cash payments amounting to RM886,091 ("Proposed Debt Settlement")

https://focusmalaysia.my/markets/second-guessing-bintai-kindens-major-shareholders-sell-out/

"Whatever the reasoning may be, Minority Shareholder Watch Group CEO Devanesan Evanson opined that the disposal of such huge chunks of shares may be perceived as a lack of confidence in the company especially since the licensing and distribution agreements have not come into operation.

“Then again, the two largest shareholders – by selling their shares – may be signalling to the market that the shares are overvalued,” he told FocusM. “But after all, they may have really needed the cash and wished to cash-out.”

While only the shareholders know the exact reasons behind their disposal, minority shareholders must nevertheless take heed of the share acquisition/disposal of major shareholders as such transactions may be telling something."

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1860
-0.0100 (-5.12%)
At close: 3:59PM EST 29 December 2020

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1950
-0.0100 (-4.88%)At close: December 24 12:39PM EST

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1965
-0.0135 (-6.43%)
At close: 3:52PM EST 22 December 2020

https://focusmalaysia.my/markets/second-guessing-bintai-kindens-major-shareholders-sell-out/

"Whatever the reasoning may be, Minority Shareholder Watch Group CEO Devanesan Evanson opined that the disposal of such huge chunks of shares may be perceived as a lack of confidence in the company especially since the licensing and distribution agreements have not come into operation.

“Then again, the two largest shareholders – by selling their shares – may be signalling to the market that the shares are overvalued,” he told FocusM. “But after all, they may have really needed the cash and wished to cash-out.”

While only the shareholders know the exact reasons behind their disposal, minority shareholders must nevertheless take heed of the share acquisition/disposal of major shareholders as such transactions may be telling something."

https://www.klsescreener.com/v2/news/view/735539/anatomy-of-stock-market-scams

Anatomy of stock market scams
TheStar Sat, Oct 03, 2020 09:40am

"Thirdly, one must look out for companies raising money through share placements, especially if the proceeds are to be used as working capital or to repay loans. "

"Also, if the bulk is used to repay loans, there is also a possibility of the company taking up more loans again. So, why risk taking up a stake in such companies?"

Bintai raised money through Private Placement to partially pay it's debts of RM160 million.

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1901
-0.0088 (-4.45%)
At close: 3:59PM EST

https://www.klsescreener.com/v2/news/view/735539/anatomy-of-stock-market-scams

Anatomy of stock market scams
TheStar Sat, Oct 03, 2020 09:40am

"Thirdly, one must look out for companies raising money through share placements, especially if the proceeds are to be used as working capital or to repay loans. "

"Also, if the bulk is used to repay loans, there is also a possibility of the company taking up more loans again. So, why risk taking up a stake in such companies?"

Bintai raised money through Private Placement to partially pay it's debts of RM160 million.

On behalf of the Board, M&A Securities wishes to announce that the Company has fixed the issue price of the Placement Shares at RM0.565 each.

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1850
-0.0125 (-6.33%)
At close: 3:59PM EST 11 November 2020

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1901
-0.0099 (-4.95%)
At close: 3:59PM EST 9 November 2020

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1950
-0.0050 (-2.50%)
At close: 3:58PM EST 4 November 2020

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3101117

On behalf of the Board, M&A Securities is pleased to announce that Bursa Securities had, vide its letter dated 28 October 2020 (received on 30 October 2020), approved the listing of and quotation for up to 31,800,000 new ordinary shares in BKCB to be issued pursuant to the Private Placement....

(i) the issuance of 28,700,000 new Shares at the issue price of RM0.52 each pursuant to
the Previous Private Placement, which raised proceeds of RM14.92 million;

(a) The Company intends to utilise RM15.0 million of the gross proceeds to partially repay the outstanding borrowings of the BKCB Group. As at 30 September 2020, the total bank borrowings of the Group (excluding lease liabilities) stood at approximately
RM155.8 million
which comprise mainly bank overdrafts, bankers acceptances, bill payables, revolving credit, term loans and hire purchase.

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.1988
-0.0130 (-6.15%)
At close: 3:59PM EDT 29 October 2020

Vaccine progress / stage tracker

https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

Search: Generex

Candidate : No name announced

Mechanism : Ii-Key peptide COVID-19 vaccine

Sponsor : Generex Biotechnology

Trial Phase : Pre-clinical

Institution : Generex

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2120
-0.0160 (-7.02%)
At close: 3:56PM EDT 22 October 2020

https://www.klsescreener.com/v2/news/view/735539/anatomy-of-stock-market-scams

Anatomy of stock market scams
TheStar Sat, Oct 03, 2020 09:40am

"Thirdly, one must look out for companies raising money through share placements, especially if the proceeds are to be used as working capital or to repay loans. "

"Also, if the bulk is used to repay loans, there is also a possibility of the company taking up more loans again. So, why risk taking up a stake in such companies?"

Bintai raised money through Private Placement to partially pay it's debts of RM160 million.

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2150
-0.0270 (-11.14%)
At close: 3:59PM EDT 19 October 2020

klse.i3investor.com
BINTAI (6998)
Avg Volume (4 weeks): 112,566,680
4 Weeks Range: 0.50 - 0.935
52 Weeks Range: 0.04 - 0.94
Average Price Target: 0.39
Price Target Upside/Downside: -0.335

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2148
-0.0282 (-11.62%)
At close: 3:58PM EDT

Changes in Director's Interest (Section 219 of CA 2016)
BINTAI KINDEN CORPORATION BERHAD

Information Compiled By KLSE

Particulars of Director
Name MR YEN YEW WING @ YEN YEW MING
Descriptions(Class) Ordinary Shares
Details of changes
No 1
Date of change 08/10/2020
No of securities 150,000
Type of transaction Disposed
Nature of Interest Direct Interest

Name of registered holder Yen Yew Wing @ Yen Yew Ming
Description of "Others" Type of Transaction
Consideration (if any) RM0.683

Circumstances by reason of which change has occurred Disposal in the open market
Nature of interest Direct Interest
Total no of securities after change
Direct (units) 297,500
Direct (%) 0.093
Indirect/deemed interest (units) 0
Indirect/deemed interest (%) 0.000
Date of notice 12/10/2020
Date notice received by Listed Issuer 12/10/2020

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3095423

Vaccine progress / stage tracker

https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

Search: Generex

Candidate : No name announced

Mechanism : Ii-Key peptide COVID-19 vaccine

Sponsor : Generex Biotechnology

Trial Phase : Pre-clinical

Institution : Generex

Here's the current state of play on vaccines and treatments.

https://www.bloomberg.com/features/2020-coronavirus-drug-vaccine-status/

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Date of transaction 07 Oct 2020
Currency Malaysian Ringgit (MYR)
Type of changes Resale
Total number of treasury shares changed (units) 200,000
Minimum price paid for each share sold ($$) 0.700
Maximum price paid for each share sold ($$) 0.700
Total consideration received ($$) 140000.00
Total number of treasury shares held after the resale or transfer 798,800
Adjusted issued capital after cancellation (no. of shares) (units) 317,492,940

02/10/2020
150,000
Disposed
Direct Interest
Name of registered holder Yen Yew Wing @ Yen Yew Ming
Description of "Others" Type of Transaction
Consideration (if any) RM0.645
2
02/10/2020
100,000
Disposed
Direct Interest
Name of registered holder Yen Yew Wing @ Yen Yew Ming
Description of "Others" Type of Transaction
Consideration (if any) RM0.640

Circumstances by reason of which change has occurred Disposal in the open market
Nature of interest Direct Interest
Total no of securities after change
Direct (units) 447,500
Direct (%) 0.141
Indirect/deemed interest (units) 0
Indirect/deemed interest (%) 0.000
Date of notice 07/10/2020
Date notice received by Listed Issuer 07/10/2020

Bursa announcements 7/10/2020

Company sold Treasury shares

Director sold shares

Changes in Director's Interest (Section 219 of CA 2016)
BINTAI KINDEN CORPORATION BERHAD

ParticChanges in Director's Interest (Section 219 of CA 2016)
BINTAI KINDEN CORPORATION BERHADulars of Director
Name MR YEN YEW WING @ YEN YEW MING
Descriptions(Class) Ordinary Shares
Details of changes
No
Date of change
No of securities

1
29/09/2020
50,000
Disposed
Direct Interest
Name of registered holder Yen Yew Wing @ Yen Yew Ming
Description of "Others" Type of Transaction
Consideration (if any) RM0.625

Circumstances by reason of which change has occurred Disposal in the open market
Nature of interest Direct Interest
Total no of securities after change
Direct (units) 697,500
Direct (%) 0.219
Indirect/deemed interest (units) 0
Indirect/deemed interest (%) 0.000
Date of notice 01/10/2020
Date notice received by Listed Issuer 01/10/2020

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2280
-0.0109 (-4.55%)
At close: 3:57PM EDT 5 October 2020

20 cents Loss making Company with huge
debts.

https://www.klsescreener.com/v2/news/view/735539/anatomy-of-stock-market-scams

Anatomy of stock market scams
TheStar Sat, Oct 03, 2020 09:40am

Thirdly, one must look out for companies raising money through share placements, especially if the proceeds are to be used as working capital or to repay loans. The smaller the amount raised through a placement, the higher the scrutiny it warrants.

Also, if the bulk is used to repay loans, there is also a possibility of the company taking up more loans again. So, why risk taking up a stake in such companies?

Bintai raised money through Private Placement to partially pay it's debts of RM160 million.

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2050
-0.0224 (-9.84%)
At close: 3:59PM EDT 1 October 2020

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092741#

Generex still waiting for Bintai to pay an
up-front licensing fee of USD2.5 million due within 2 weeks from 18/9/2020.

No payment means MOU is for show?

GNBT - Generex Biotechnology Corporation
Other OTC - Other OTC Delayed Price. Currency in USD
0.2274
-0.0061 (-2.63%)
At close: 3:58PM EDT

In earlier post someone posted this warning.

Directors already sold shares before PP.

DATUK SHARIFAH KADNARIAH BINTI SYED AHMAD 11-Sep-2020 Disposed 20,000 0.460 View Detail
MR YEN YEW WING @ YEN YEW MING 08-Sep-2020 Disposed 150,000 0.540 View Detail
MR YEN YEW WING @ YEN YEW MING 07-Sep-2020 Disposed 100,000 0.590 View Detail
DATUK SHARIFAH KADNARIAH BINTI SYED AHMAD 12-Mar-2020 Disposed 50,000 - View Detail
DATUK SHARIFAH KADNARIAH BINTI SYED AHMAD 15-Jan-2020 Disposed 50,000 - View Detail
SHARIFAH KADNARIAH BINTI SYED AHMAD 31-Dec-2019 Disposed 54,800 - View Detail
DATUK SHARIFAH KADNARIAH BINTI SYED AHMAD 23-Dec-2019 Disposed 660,800 0.005

Private Placement price 52 sen.

Is this the reason why operators blocking sell down?

All replies to Bursa queries are only general and non committal.

Bintai answer everything at infancy stage, thus no figures provided to Bursa.

However, Generex already disclosed figures
(in USD).

4. As outlined in the MOU, Bintai will pay Generex the following fees:
a. $2,500,000 - Intellectual Properties “IP” Assignment Rights
b. $100,000 – Regulatory Fees
c. $25,000 – Legal Fees
d. $7,500,000 – Government of Malaysia Licensing Fees
e. $10,000,000 – Private Sector Licensing Fees
f. $3.00 Per Dose – Government of Malaysia Royalties Fees
g. $4.50 Per Dose - Private Sector Royalties Fees

Why the above USD figures not disclosed to Bursa?

Bursa queried JV with IJN.

See Bursa announcement on 9 September 2020.

How money raised from private placement is utilised .